Should repeat ablation be viewed as strategic rather than salvage in refractory colorectal cancer liver metastasis?

Abstract

Recent evidence suggests that repeated application of radiofrequency ablation in patients with colorectal liver metastases who have progressed after systemic chemotherapy can provide survival outcomes comparable to those achieved with single ablation. This development challenges the traditional view that repeat ablation serves only as a last-line measure and instead supports its consideration as a strategic component of long-term disease control. Tumor size appears to be a primary determinant of local treatment effect, likely reflecting interactions among thermal energy distribution, vascular perfusion, and microenvironmental conditions that influence ablative margin integrity and recurrence risk. Beyond technical feasibility, the clinical value of staged ablation depends on its integration with systemic therapies and on timely intervention based on radiologic evidence of viable disease. Thoughtful selection of candidates, including assessment of intrahepatic tumor burden, functional hepatic reserve, and absence of uncontrolled extrahepatic spread, is essential for maximizing benefit. Repeat ablation may function as a bridging approach to resection or transplantation, a consolidation method to sustain remission after chemotherapy response, or a long-term strategy to maintain disease stability and quality of life. Continued prospective evaluation incorporating biological profiling and treatment sequencing is needed to define optimal use and fully realize its therapeutic potential.

Key Words: Colorectal liver metastases; Radiofrequency ablation; Repeat ablation; Locoregional therapy; Tumor microenvironment; Liver functional reserve; Hepatic tumor burden; Thermal injury mechanism; Long-term disease control; Treatment sequencing

Core Tip: Repeated radiofrequency ablation in patients with chemotherapy-refractory colorectal liver metastases can no longer be viewed solely as a salvage procedure. When guided by radiologic evidence of viable tumor enhancement and applied in a staged manner, repeat ablation may function as an active, strategy-driven modality for sustained disease control. By integrating tumor size, hepatic reserve, and absence of uncontrolled extrahepatic spread into candidate selection, repeat ablation can serve as a bridge to resection or transplantation, a consolidation method after partial systemic response, or a long-term approach to maintain quality of life.

TO THE EDITOR

We were pleased to read the valuable study by Gao et al[1], which explored the role of radiofrequency ablation (RFA) in patients with multifocal colorectal liver metastases (CRLM) who had progressed after systemic chemotherapy. The authors demonstrated that repeated RFA can achieve survival outcomes comparable to single-session procedures, offering new therapeutic possibilities for a population traditionally regarded as unsuitable for curative intervention. This work provides meaningful clinical insight and contributes to the evolving understanding of locoregional treatment strategies in advanced CRLM.

Although the study advances the field, several key aspects merit further discussion and expansion. First, the authors’ findings emphasize tumor size as the most critical prognostic factor, with meaningful cut-off values for overall and progression-free survival. However, the biological rationale underlying size-dependent ablation response warrants deeper exploration. Factors such as thermal energy distribution, tumor vascularization, and microenvironmental heterogeneity likely influence the ablative margin and recurrence risk[2]. These factors are intrinsically interconnected: Vascularization influences thermal energy distribution by modulating blood flow and heat dissipation, while both vascular perfusion and thermal signaling shape the tumor microenvironment. For example, vascular normalization can enhance heat transfer during high-temperature thermal ablation and alleviate hypoxia, thereby improving tumor sensitivity to ablative intervention. Likewise, thermal intervention can remodel the metabolic landscape of the tumor microenvironment, with the potential to reverse immune-suppressed conditions[3]. Future studies integrating radiomics, perfusion imaging, and microenvironmental profiling may strengthen the mechanistic interpretation and optimize patient selection[4].

Second, the clinical positioning of repeated RFA needs further refinement within the broader treatment algorithm for CRLM. While the study shows that staged ablation is feasible, its optimal combination with systemic therapies such as hepatic artery infusion chemotherapy, targeted agents, or immunotherapy remains undefined. Prospective trials evaluating sequential or concurrent strategies could help determine whether repeated ablation is best used as a bridging therapy, consolidation approach, or long-term disease control modality. Additionally, exploration of microwave ablation or irreversible electroporation may enhance local control for lesions larger than the 2.7 cm threshold[5,6]. However, based on prior clinical experience, we believe that pathway formulation should fully align with the current trend toward personalized and dynamic evolution in locoregional tumor management. Optimal candidate selection should integrate the number of intrahepatic lesions, hepatic functional reserve, control or quiescence of extrahepatic disease, and the presence of viable lesions in patients who exhibit partial response or stable disease after systemic therapy but still require local consolidation. The timing of intervention should be guided by radiological evidence of viable enhancement rather than waiting for volumetric progression. Early reintervention is recommended to preserve the ablative margin and prevent microvascular expansion.

Third, given the retrospective nature of the study, patient-level variability in systemic treatment, tumor biology, and performance status may have influenced outcomes. A multidimensional integrated analysis incorporating clinical variables, tumor genomics, and treatment sequencing will be essential to develop predictive models for repeated intervention benefit. Artificial intelligence-based decision frameworks and multi-center prospective registries may accelerate evidence generation and help define personalized ablative pathways in CRLM. To more concretely delineate the potential mechanisms by which repeat ablation confers survival benefit in selected patient subgroups, it is necessary to integrate both survival curve findings and tumor progression-related parameters. The study indicates a clear separation trend in overall survival curves at the tumor size threshold, while further identifying tumor size, lesion burden, and the presence of extrahepatic disease as primary drivers of progression. Based on these observations, we propose a pragmatic, subgroup-oriented interpretation: In patients with lesions > 2.7 cm but without extrahepatic spread, a planned, staged repeat-ablation strategy aimed at sequential cytoreduction while maintaining adequate ablation margins may represent a clinically reasonable approach to reduce intrahepatic tumor burden and potentially prolong disease control. This hypothesis is informative but remains exploratory and warrants validation through dedicated subgroup analyses and prospective trials.

CONCLUSION

In conclusion, overcoming the therapeutic limitations in chemotherapy-refractory multifocal CRLM requires a paradigm shift from single-session interventions to dynamic, staged local control strategies. The study by Gao et al[1] represents an important step toward redefining the role of RFA in this context, supporting its use as an active component of long-term disease management rather than a last-line palliative tool. Continued investigation integrating mechanistic biology, multi-modal therapy design, and prospective clinical evaluation will be key to fully realizing the potential of repeated RFA in advanced CRLM. Strategic repeat RFA may serve as a bridging modality to resection or transplantation, a consolidation strategy to sustain remission, or a long-term disease stabilization method to maintain functional status and quality of life.